0 -O-(2-thiodiphosphate) (ADPbS), the P2X 1,3 receptor agonist a,b-methylene ATP (a,bmeATP), the unspecific P2 receptor antagonist pyridoxalphosphate-6-azopheny l-2 0 ,4 0 -disulfonic acid (PPADS), and the specific P2Y 1 receptor antagonist N 6 -methyl-2 0 -deoxyadenosine-3 0 ,5 0 -bisphosphate (MRS 2179) on the elevated plus-maze behavior of the rat were investigated. All tested compounds were given intracerebroventricularly (0.5 ml). ADPbS (50 and 500 fmol) produced an anxiolytic-like behavioral profile reflected by an increase of the open arm exploration. The anxiolytic-like effects were antagonized by pretreatment with PPADS (5 pmol) or MRS 2179 (5 pmol). Both compounds caused anxiogenic-like effects when given alone. Furthermore, the anxiolytic-like effects of ADPbS could be antagonized by pretreatment with the nitric oxide synthase (NOS) inhibitor N w -nitro-L-arginine methyl ester (L-NAME). In addition, the anxiogenic-like effects of PPADS were reversed by the pretreatment with L-arginine (500 pmol), which is the natural substrate for NOS, but not by D-arginine (500 pmol), which is not. Immunofluorescence staining revealed the presence of P2Y 1 receptors on neurons in different brain regions such as hypothalamus, amygdala, hippocampus and the periaqueductal gray. Furthermore, the colocalization of P2Y 1 receptors and neuronal NOS (nNOS) on some neurons in these regions could be demonstrated. The highest density of P2Y 1 -and nNOS-immunoreactivity was detected in the dorsomedial hypothalamic nucleus. Taken together, the present results suggest that P2Y 1 receptors are involved in the modulation of anxiety in the rat. The anxiolytic-like effects after stimulation of P2Y 1 receptors seem to be in close connection with the related nitric oxide production.
INTRODUCTION
In previous studies, it has been demonstrated that stimulation of P2 receptors, which belong either to the P2X ligandgated ion channel family (P2X 1-7 subtypes) or to the P2Y G protein-coupled receptor family (P2Y 1, 2, 4, 6, 11, 12 subtypes) (Ralevic and Burnstock, 1998; Bürnstock, 2001) , is involved in the regulation of locomotion as well as in the expression of sensitization and reward (Kittner et al, 2001; Krügel et al, 2001a) . It has been shown that the open field behavior after intra-accumbal injection of the adenosine 5 0 -triphosphate (ATP) analog 2-methylthio ATP (2-MeSATP) is characterized by an extended period of novelty-induced locomotion and additionally, after a latency time, by an increased exploration of the inner open field areas indicating anxiolytic-like properties of the P2 receptor agonist (Kittner et al, 1997) . The aim of the present study was to clarify whether P2 receptors are involved in the regulation of fear and anxiety. For this purpose, the influence of the P2Y 1, 11, 12 receptor agonist adenosine 5 0 -O-(2-thiodiphosphate) (ADPbS), the P2X 1,3 receptor agonist a,b-methylene ATP (a,bmeATP), the nonspecific P2 receptor antagonist pyridoxalphosphate-6-azopheny L-2 0 ,4 0 -disulfonic acid (PPADS), the P2Y 1 receptor-specific antagonist MRS 2179, and the combination of the respective agonists and antagonists on the elevated plus-maze behavior of rats was investigated after intracerebroventricular (i.c.v.) injection.
After the stimulation of P2Y 1 receptors by the physiological agonist adenosine 5 0 -diphosphate (ADP) (You et al, 1997) as well as by its analog ADPbS (Malmsjö et al, 1999; Rump et al, 1998) , an enhanced formation of the free radical gas nitric oxide (NO) was observed. NO is known to be synthesized from L-arginine and oxygen by NO synthase (NOS) in the presence of NADPH, and plays a role in various signal transduction processes in the CNS. Three distinct isoforms of NOS have been identified: neuronal NOS (nNOS)Fthe isoform predominating in neuronal tissue, inducible NOS (iNOS)Fthe inducible isoform found in many cells and tissues, and the endothelial NOS (eNOS)Fthe isoform located in vascular endothelial cells (Alderton et al, 2001) . It has been demonstrated that extracellular ATP induces a rise in cyclic GMP level, which is caused by Ca 2+ -activated formation of NOS (Reiser, 1995) . Therefore, any interaction between the P2 receptormediated signaling pathway and the NO system is of particular interest. There is growing evidence that NO is involved in the regulation of anxiety, although some controversial results have been reported. On the one hand, the NOS inhibitor N g -nitro-L-arginine (L-NOARG) abolished the anxiolytic-like effects of NO (Caton et al, 1994) as well as of chlordiazepoxide (Quock and Nguyen, 1992) , and the NOS inhibitor N w -nitro-L-arginine methyl ester (L-NAME) produced anxiogenic-like effects in the rat elevated plusmaze (Vale et al, 1998) . On the other hand, an anxiolyticlike action of L-NAME has also been reported in the same model (Volke et al, 1995) .
The present study aimed to clarify whether the P2Y 1 receptor-mediated effects on anxiety are correlated with an enhanced availability of NO. Therefore, the influence of L-NAME and L-arginine on the P2Y 1 receptor-mediated effects on anxiety was studied. To clarify the possibility of a colocalization of P2Y 1 receptors and nNOS at the same neurons as a condition for a direct relation between P2Y 1 receptor stimulation and NO release, immunohistochemical studies were carried out in relevant brain regions, for example, the hypothalamus, amygdala, hippocampus, and periaqueductal gray, which are involved in the regulation of fear and anxiety.
MATERIALS AND METHODS

Animals
Adult male Wistar rats (WIST/Lei) weighing 300-320 g were used. The animals were housed under standardized humidity, temperature, and lighting conditions with a 12-h/12-h light/dark cycle (lights on at 7.00 am) and had free access to water and food. The animals were housed four or five per cage before and individually after surgery. The experiments were approved by the Committee on Animal Care and Use of the relevant local governmental body according to the German guidelines (BGBl.I p.1105) revised in 1998. All efforts were made to minimize the number of animals used and their suffering.
Drugs
All drugs were diluted and applied in artificial cerebrospinal fluid (aCSF; 126 mM NaCl, 2.5 mM KCl, 1.2 mM NaH 2 PO 4 , 1.3 mM MgCl 2 , and 2.4 mM CaCl 2 ; pH 7.4). ADPbS and a,bmeATP were obtained from Sigma-Aldrich (Chemie GmbH, Deisenhofen, Germany). (L-NAME), L-and Darginine were purchased from Tocris Cookson Ltd, (Bristol, UK) and N 6 -methyl-2 0 -deoxyadenosine-3 0 ,5 0 -bisphosphate (MRS 2179) from RBI (Natick, MA, USA).
Surgery and i.c.v. Injections
Rats were anesthetized with a combination of ketamine hydrochloride (100 mg/kg, i.p.; Ketanest s , Ratiopharm, Ulm, Germany) and xylazine hydrochloride (5 mg/kg, i.p.; Rompun s , Bayer, Leverkusen, Germany). Following placement in a stereotaxic frame, they were implanted with a 24-gauge guide cannula (bioflow catheters; Vygon, Ecouen, France). To avoid a permanent injury of the ventricle, the implanted guide cannula was placed immediately above it. The stereotaxic coordinates according to Paxinos and Watson (1986) were: AP ¼ À1 mm rostral to bregma, ML ¼ +1.5 mm lateral to the sagittal suture, DV ¼ À2.5 mm mm below the surface of the hemisphere. The cannula was embedded in a socket mounted on the skull in dental acrylic cement (Technovit s 3040; Heraeus Kulzer, Wehrheim, Germany) and additionally fixed by two stainless-steel screws. After surgery, the animals were treated with benzyl penicillin (200.000 IE, i.m.; Retacillin compositum s , Jenapharm, Jena, Germany) for antibiotic prophylaxis and were allowed to recover for 6 days by individually housing before the maze exposure. The individually harbored animals showed only a slight, but no significant, tendency to higher anxiety-like behavior in comparison with the grouped, housed control animals.
The i.c.v. injections were made in freely moving rats, which were habituated to the injection procedure 2 or 3 days before the beginning of the experiments. Injection cannulae (26 gauge) connected to 10 ml syringes via PE-20 tubing were inserted into the guide cannula and protruded 1.5 mm beyond its end to reach the ventricle. All compounds were infused in a volume of 0.5 ml over 3 min using a microinfusion pump (TSE GmbH, Bad Homburg, Germany). The injection cannula was left in place for an additional minute after the application to allow diffusion of the solution. The purinergic agonists ADPbS and a,bmeATP, the P2Y 1 receptor antagonist MRS 2179 as well as L-and D-arginine were administered 5 min before the maze performance. The P2 receptor antagonist PPADS and L-NAME were injected 15 and 30 min, respectively, before the start of the maze exposure. Animals that received only antagonists or agonists got the vehicle as second injection. For histological evaluation, the animals received an i.c.v. injection of methylene blue and were killed by decapitation after completion of the experiments. Only rats showing the appropriate injection site were used for data analysis.
Elevated Plus-Maze
The elevated plus-maze is a widely used and extensively validated animal model of anxiety based on the natural aversion of rodents for open spaces and on the elevation of the maze (Handley and Mithani, 1984; Pellow et al, 1985) .
The apparatus was made of wood with a black rubber floor. It consisted of two open arms (50 Â 10 cm) and two enclosed arms (50 Â 10 cm) with walls of 40 cm height, elevated 50 cm above the ground. The arms of the same type were opposite to each other, connected by an open central area (10 Â 10 cm). A camera was mounted vertically above the maze, and the behavior was scored from a monitor in an adjacent room. The investigation room was illuminated with a light intensity of 500 lx, resulting in a brightness of 650 lx at the open and 200 lx at the enclosed arms of the maze. At the beginning of the experiment, rats were placed in the center of the maze, facing the enclosed arms, and were observed for 10 min. Each animal was tested only once. Eight rats were tested at each dose for each compound. All tests were carried out between 0800 and 1300 h. (Pellow et al, 1985) , whereas the number of entries into enclosed arms provides a measure of general activity (File, 1991) .
Double Immunofluorescence
The rats were transcardially perfused under thiopental sodium anesthesia with paraformaldehyde (2%) in sodium acetate buffer (pH 6.5) followed by paraformaldehyde (2%)/glutaraldehyde (0.1%) in sodium borate buffer (pH 8.5). Serial sections (50 mm thick) from the dorsomedial hypothalamic nucleus, the basomedial nucleus amygdala, the dorsal hippocampus ( Figure 1 ) as well as from the periaqueductal gray (not shown) were obtained by using a vibratome (TSE, Bad Homburg, Germany) and collected as free-floating slices in 0.1 M Tris (pH 7.6).
P2Y 1 -immunofluorescence was performed as previously described (Franke et al, 2001) . Briefly, after washing with Tris buffered saline (TBS, 0.05 M; pH 7.6) and blocking with 5% fetal calf serum (FCS) in TBS, the slices were incubated in an antibody mixture of rabbit anti-P2Y 1 receptor antibody (1 : 1500, SmithKline Beecham Pharmaceuticals, Hertord shire, UK) and mouse anti-NOS (NOS1, 1 : 1000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) with 0.1% Triton X-100 in 5% FCS in TBS for 48 h at 41C. Subsequently, the slices were incubated with the two secondary antibodies Cy3-conjugated goat anti-rabbit IgG (1 : 800; Jackson Immuno Research) and Cy2-conjugated goat anti-mouse IgG (1 : 400; Jackson Immuno Research, Baltimore, USA) in 5% FCS in TBS for 2 h. After intensive washing and mounting on slide glasses, all stained sections were dehydrated in a series of graded ethanol, processed through n-butylacetate, and covered with entellan (Merck, Darmstadt, Germany). Control experiments were carried out without primary antibodies.
Confocal Microscopy
The double immunofluorescence was investigated by a confocal laser scanning microscope (LSM 510, Zeiss, Oberkochen, Germany) equipped with an argon laser emitting at 488 nm and a helium/neon laser emitting at 543 nm. The two reaction products were distinguished by their different fluorescence: nNOS by the green Cy2 immunofluorescence and the P2Y 1 receptor subtype by the red Cy3 immunofluorescence.
Statistics
All results were expressed as means 7 SEM (n ¼ 8). In experiments using the elevated plus-maze, the percentage of time spent on the open arms (open Â 100/open+enclosed) and the percentage of open arms entries (open Â 100/total entries) were calculated for each animal. Additionally, the number of enclosed arm entries was recorded. To evaluate statistical differences in the elevated plus-maze experiments, one-way analysis of variance (ANOVA) was used followed by the Student-Newman-Keuls test for multiple comparisons. A probability level of po0.05 was considered to be statistically significant.
RESULTS
Influence of ADPbS on the Rat Elevated Plus-Maze Behavior
ADPbS had a significant dose-related anxiolytic-like effect, shown by an increase in the percentage of time spent on the open arms (F(5,47) ¼ 25.6, po0.001) (Figure 2 ) and the Table 1) . None of the drugs had a significant effect on the number of enclosed arms entries in comparison with the aCSF control group (F(5,47) ¼ 2.5). Significant differences were found only at 500 fmol ADPbS in comparison with the lower doses of 5 and 50 fmol of this compound (po0.05) (Table 1) .
Furthermore, the influence of the P2Y 1 -receptor antagonist MRS 2179 (5 pmol) on the effects of 50 fmol ADPbS was studied. After pretreatment with MRS 2179, the anxiolytic-like effects of ADPbS (50 fmol) were abolished (F(3,31) ¼ 38.2, po0.001). MRS 2179 (5 pmol) alone exerted anxiogenic-like properties (po0.001) (Figure 3 ; Table 1 ).
Influence of a,bmeATP on the Rat Elevated Plus-Maze Behavior (Table 1) . Furthermore, the ANOVA for the number of enclosed arm entries revealed no significant effect of a,bmeATP on the general locomotor activity (F(3,31) ¼ 0.27) ( Table 1) .
Influence of L-NAME on the Rat Elevated Plus-Maze Behavior
As shown in Figure 5 , L-NAME (0.05-5 nmol) produced a dose-dependent decrease in the percentage of time spent on the open arms (F(5,47) ¼ 19.2, po0.001). The decrease in the percentage of open arms entries reaches statistical significance at 5 nmol L-NAME (F(5,47) ¼ 6.5, p ¼ 0.001). The number of enclosed arm entries was unaltered at all tested doses (F(5,47) ¼ 1.3, p ¼ 0.28) ( Table 2 ). The effects of L-NAME (0.5 nmol), were abolished by the pretreatment with L-arginine (0.5 nmol), indicating that the anxiogeniclike effect of L-NAME is caused by a decreased NO synthesis. 
Immunohistochemistry
Immunohistochemical staining revealed the presence of P2Y 1 receptors on neurons in relevant brain regions such as hypothalamus, amygdala, hippocampus, and periaqueductal gray, which are known to be involved in the regulation of anxiety and fear. Especially the labeling of the dorsomedial nucleus of the hypothalamus shows a high density of P2Y 1 -immunoreactivity (IR) (Figure 8b and e). A weakly expressed P2Y 1 IR was found in the basomedial nucleus of the amygdala (Figure 8h ) and the dorsal hippocampus, for example in the CA3 region (Figure 8k ). In the basolateral nucleus of the amygdala and the periaqueductal gray, only scarce P2Y 1 -IR was detected (data not shown). The labeling of nNOS reveals a high density in the dorsomedial hypothalamus (Figure 8a and d) . The expres- administration of L-NAME in various doses in comparison with vehicle (aCSF)-treated controls and 5 min after L-arginine (L-ARG) with and without pretreatment with L-NAME (0.5 nmol). *po0.05, **po0.02, ***po0.001 compared with the vehicle-treated controls, + po0.05 compared with the L-NAME (0.5 nmol) group, Student-Newman-Keuls test after one-way ANOVA. sion of nNOS-IR in the basomedial nucleus amygdala and the hippocampal CA3 region (Figure 8g and j) was considerably lower. The colocalization of P2Y 1 -IR and nNOS-IR at various neurons in the studied regions is documented in Figure 8 (f, i, l).
DISCUSSION
The metabolically stable P2 receptor agonist ADPbS, preferential for adenine nucleotide-sensitive P2Y 1 , P2Y 11 , and P2Y 12 receptors, produced anxiolytic-like effects in the rat elevated plus-maze after i.c.v. administration at doses between 5 and 500 fmol. Both the percentage of time spent on the open arms and the percentage of open arm entries were increased by this ADP analog. The highest tested dose of ADPbS (500 fmol) significantly decreased the enclosed arm entries that were used as an indicator of drug-induced changes of general locomotor activity. It has been shown that the effects of compounds on the elevated plus-maze behavior such as amphetamine were confounded by an increase of general activity . In the turned around sense, a decreased locomotion could be responsible for the tendency to a weaker anxiolytic-like effect after 500 fmol ADPbS in comparison with 50 fmol. An attenuated locomotor response could be a result of a predominant activation of presynaptic dopamine D2 autoreceptors in the nucleus accumbens or the striatum (Hu and Wang, 1988 ) after a slightly enhanced dopamine release induced by the ADP analog. Another explanation could be a P2 receptor-mediated glutamate release in the same area (Krügel et al, 2001b) , which is known to reduce locomotor activity (Schmidt and Kretschmer, 1997) . The high potency of ADPbS to produce anxiolytic-like effects agrees with various in vitro studies that documented the high affinity of ADPbS to bind to rat brain P2Y 1 receptors (Vöhringer et al, 2000) . It seems unlikely that P2Y 2 , P2Y 4 , or P2Y 6 receptors are involved in the ADPbS response for the tested doses.
Pretreatment with the P2 receptor antagonist PPADS abolished the ADPbS-induced effects. The anxiogenic-like effects of PPADS alone suggest that an endogenous ATP acting at P2 receptors is involved in the regulation of anxiety and fear. PPADS is a nonselective P2 receptor antagonist. In addition to the blockade of various P2X receptors, PPADS also acts as an effective antagonist at the P2Y 1 receptor, whereas it is completely ineffective at the P2Y 11 receptor (Communi et al, 1999) . PPADS does not recognize P2Y 2 receptors up to a concentration of 30 mM and is also a relatively ineffective antagonist at the uridine nucleotide-sensitive P2Y 4 and P2Y 6 receptors (Charlton et al, 1996; Bogdanov et al, 1998; Dol-Gleizes et al, 1999) . PPADS also fails to block P2Y 12 receptor-mediated effects (Nicholas, 2001) . It has been shown that only P2Y receptors coupled to phospholipase C, but not those negatively coupled to adenylate cyclase, were inhibited by PPADS (Boyer et al, 1994) . In this view, the anxiolytic-like effect of ADPbS appears to be mediated by an activation of phospholipase C, leading to the production of inositol-1,4,5-trisphosphate (IP 3 ) and to the mobilization of intracellular Ca 2+ resulting in the stimulation of a variety of signaling pathways such as protein kinase C, phospholipase A 2, Ca 2+ -dependent K + -channels as well as NOS and subsequent NO formation.
It is thought that neither cell death (Chan and Lin-Shiau, 2001 ) nor unspecific effects of PPADS such as the inhibition of ectonucleotidase activity (Windscheif et al, 1995) or the inhibition of IP 3 -induced Ca 2+ mobilization by a nonspecific mechanism (Vigne et al, 1996) contribute to the PPADS-mediated effects at the tested dose. Furthermore, it should be emphasized that in contrast to the P2 receptor antagonists suramin and reactive blue 2 no direct glutamate antagonistic properties were found for PPADS (Fröhlich et al, 1996; Motin and Bennett 1995; Gu et al, 1998) . The anxiolytic-like effects of ADPbS were also abolished after pretreatment with MRS 2179, which acts as a specific P2Y 1 receptor antagonist (Boyer et al, 1998) . MRS 2179 alone produced anxiogenic-like effects similar to those caused by PPADS, suggesting that the blockade of P2Y 1 receptors is mainly involved in mediating the PPADS-induced anxiety.
No effects were observed after i.c.v. administration of a,bmeATP up to doses of 5 nmol. This ATP analog, which is resistant to enzymatic degradation (Kennedy and Leff 1995) , acts on homomeric P2X 1 and P2X 3 receptors as well as on heteromeric P2X 4 /P2X 6 receptors, but it is known to be inactive at P2Y receptors (Ralevic and Burnstock, 1998; Nörenberg and Illes, 2000) . In this view, an involvement of P2X receptors on the regulation of anxiety appears unlikely, although it cannot be completely excluded.
The unspecific NOS inhibitor L-NAME produced dosedependent anxiogenic-like effects. These results conform with studies of Vale et al (1998) after intraperitoneal (i.p.) injection of L-NAME. Anxiogenic-like effects after the inhibition of NOS were also reported by other authors. For example, the NOS inhibitor L-NOARG decreased the exploration of an elevated plus-maze system (De Oliveira et , 1997) and was able to antagonize the anxiolytic-like effects of NO (Caton et al, 1994) as well as of chlordiazepoxide (Quock and Nguyen, 1992) . Anxiogenic-like effects were also reported after intra-amygdala or intra-hippocampal injection of L-NOARG (Monzon et al, 2001) . On the one hand, eNOS-deficient mice showed an increase in anxietyrelated behavior in the plus-maze in comparison with the wild-type controls (Frisch et al, 2000) . On the other hand, anxiolytic-like effects of L-NAME have been reported in the rat elevated plus-maze after i.p. injections (Volke et al, 1995) as well as after administration into the periaqueductal gray area (Guimaraes et al, 1994) . However, in both studies the anxiolytic-like response occurred only in a small dose range at lower doses, whereas at higher doses anxiogeniclike effects became apparent. In the present study, a weak but significant anxiolytic effect of L-arginine alone was observed, whereas other authors failed to show any anxiolytic effects of L-arginine on the elevated plus-maze (Yildiz et al, 2000 , Volke et al, 1997 . Possible reasons for these incompatible findings may consist in a different basal tonus of fear in the animals used and in different application routes. The discussion of inconsistent results from studies using the elevated plus-maze had also to consider that there are different stages of the elevated plus-maze behavior. At first, a stimulation of anxiety-like behavior may result in a facilitated passive avoidance response. The animals remain in the enclosed arms. A more potent stimulation of anxietylike behavior may result in a situation in which the animal is motivated to search for an escape route from the maze (Kalynchuk et al, 1998) . In the present study, the increased anxiety-like behavior after L-NAME as well as after PPADS and MRS 2179 administration resulted in a stimulation of passive avoidance (animals remained in the enclosed arms) without stimulation of the escape behavior.
To avoid the cardiovascular effects of L-NAME, the compound was administered into the lateral ventricle (Rees et al, 1990) . It has been shown that the i.c.v. administration of L-NAME did not cause any alteration of blood pressure and heart rate (Hamada et al, 1995; Chikada et al, 2000) . Considering the distribution properties of NOS inhibitors after application into the lateral ventricle (Greenberg et al, 1997; Salter et al, 1995) , only regions in close proximity to the ventricle such as the thalamus, the hypothalamus or the striatum are possible targets for mediating the anxiogeniclike effects after L-NAME application.
Although the nNOS is the predominant isoenzyme of NOS in the neuronal tissue, a contribution of eNOS or iNOS to the L-NAME-evoked effects cannot be excluded. The selective nNOS inhibitor 7-nitroindazole is not an alternative to L-NAME in this respect, because of its monoamine oxidase (MAO)-B inhibitory effects (Castagnoli et al, 1997; Royland et al, 1999) . MAO inhibitors were shown to have anxiolytic-like properties in the elevated plus-maze (Griebel et al, 1998) .
Pretreatment with the NOS inhibitor L-NAME not only led to an expression of enhanced anxiety, but also completely abolished the anxiolytic-like effects of ADPbS, suggesting that these effects are in close relation to enhanced NO formation. Considering the assumption that NOS is stimulated by an increase of intracellular Ca 2+ , L-NAME acts downstream to the P2 receptor-mediated effects. In fact, ADPbS did not attenuate the L-NAME-induced anxiety.
The influence of the pretreatment with L-and D-arginine on the PPADS-mediated effect was also investigated in this study. When PPADS pretreated rats obtained L-arginine, the anxiogenic-like influence of PPADS on the elevated plusmaze behavior was abolished, while by the treatment with Darginine the PPADS-mediated effect remained unchanged.
In summary, the results of these experiments demonstrate that NO is involved in mediating the behavioral effects of P2Y 1 receptor stimulation. Confirming this possibility, the blockade of the P2 receptors by PPADS may lead to a decrease of the NO release, an effect that is synergistic with the action of NOS inhibitors. Further evidence for a close relationship between P2 receptors and NO production is given by a study of Liu et al (2000) , which shows that pretreatment of astrocytes with P2 receptor antagonists including PPADS results in a down regulation of interleukin-1b-stimulated NOS expression.
The present immunohistochemical data show a distribution of the P2Y 1 receptors in the rat brain, which agrees well with that observed in human brain (Moore et al, 2000) . From CNS areas known to be involved in the regulation of anxiety and fear, the highest density of P2Y 1 -IR was found in the area of the dorsomedial hypothalamus. Moreover, a considerable part of the neurons in this hypothalamic nucleus showed a coexpression of P2Y 1 receptor-and nNOS-IR. The dorsomedial hypothalamus is associated with various physiological functions such as the regulation of anxiety and the modulation of food intake (Vanhatalo and Soinila, 1998; Shekhar and Keim, 1997) . For example, the blockade of GABA A receptors in the dorsomedial hypothalamus increases corticosterone and ACTH plasma levels (Keim and Shekhar, 1996) , whereas lesion of this nucleus causes anxiolytic-like effects (Inglefield et al, 1994) . In the present study, immunohistochemical staining has demonstrated that P2Y 1 receptors and nNOS are colocalized in a population of neurons in the dorsomedial hypothalamus. Therefore, it is conceivable that this area is at least one possible site of action participating in the P2Y 1 receptormediated effects on fear and anxiety. This assumption is supported by preliminary experiments with infusion of ADPbS (50 fmol) directly into the dorsomedial hypothalamus. The ADPbS-treated animals showed a significant decrease in anxiety, but no changes in locomotor activity (H Kittner, unpublished observation) .
An inhibition of the dorsomedial hypothalamus after stimulation of P2Y 1 receptors may be mediated by an activation of the NO-cyclic GMP pathway, followed by an opening of ATP-sensitive K + channels. P2Y 1 -and nNOS-IR was found to a lesser extent in the basomedial amygdala and the dorsal hippocampus.
Although only a small number of neurons showing P2Y 1 -and nNOS-IR was found in the basolateral amygdala and the periaqueductal gray, we cannot reliably exclude an involvement of these structures in the elevated plus-maze behavior. It has been shown that NO release, for example, only from few non-noradrenergic neurons in the locus coeruleus may influence a large population of noradrenergic neurons, which in turn may control the neuronal activity in various brain regions (Xu et al, 1998) . Nevertheless, it seems unlikely that the basomedial amygdala and the dorsal hippocampus considerably participate in the ADPbSinduced anxiolytic-like response because the basomedial amygdala is mainly involved in mediating feeding and social behavior as well as emotion-related learning (Petrovich et al, 1996) . The dorsal hippocampus does not seem to play an important role in controlling the behavior during the first exposure to the plus-maze system (Treit and Menard 1997; File et al, 1998 File et al, , 2000 .
In conclusion, the results of the present study reveal that P2Y 1 receptors are involved in the modulation of anxiety. The anxiolytic-like effects after stimulation of the P2Y 1 receptor seem to be in close relationship with the ensuing formation of NO.
